v3.26.1
NATURE OF BUSINESS AND ORGANIZATION (Details)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Sep. 30, 2022
USD ($)
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
May 05, 2026
USD ($)
NATURE OF BUSINESS AND ORGANIZATION                  
Accumulated deficit   $ 281,718,099       $ 281,718,099   $ 269,133,500  
Net loss   6,930,653 $ 5,653,946 $ 5,447,911 $ 6,604,029 12,584,598 $ 12,051,940    
Cash flows from operations           10,855,742 14,498,960    
Unrestricted cash and cash equivalents           $ 29,000,000      
Additional securities purchase agreement, upfront                 $ 35,000,000
Additional securities purchase agreement, milestone based                 $ 105,000,000
Number of reportable segments | segment           1      
Fixed asset impairment charges           $ 0 0    
Unrecognized Tax Benefits, Period Increase (Decrease)           0   0  
Uninsured cash balances   $ 33,744,000       33,744,000   $ 12,946,000  
Cancer treatment research award through the National Cancer Institute (NCI)                  
NATURE OF BUSINESS AND ORGANIZATION                  
Grant received $ 1,980,000         $ 2,000,000      
Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]           Costs and Expenses      
Period over which cancer treatment research award was received.           3 years      
Reduction in research and development           $ 0 $ 0    
Leasehold improvements                  
NATURE OF BUSINESS AND ORGANIZATION                  
Property and equipment useful lives   64 months       64 months      
Minimum                  
NATURE OF BUSINESS AND ORGANIZATION                  
Property and equipment useful lives   3 years       3 years      
Share-based compensation expiration period           12 months 12 months    
Maximum                  
NATURE OF BUSINESS AND ORGANIZATION                  
Property and equipment useful lives   10 years       10 years      
Share-based compensation expiration period           3 years 3 years